Profile data is unavailable for this security.
About the company
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
- Revenue in USD (TTM)0.00
- Net income in USD-67.45m
- Incorporated2017
- Employees55.00
- LocationDesign Therapeutics Inc6005 Hidden Valley Road, Suite 110CARLSBAD 92011United StatesUSA
- Phone+1 (858) 293-4900
- Fax+1 (302) 636-5454
- Websitehttps://www.designtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alto Neuroscience Inc | 0.00 | -62.26m | 510.73m | 76.00 | -- | 4.00 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Altimmune Inc | 20.00k | -83.92m | 515.65m | 59.00 | -- | 2.35 | -- | 25,782.48 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 535.58m | 95.00 | -- | 3.98 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 536.98m | 144.00 | -- | -- | -- | 12.19 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 539.17m | 300.00 | -- | 1.49 | -- | 13,150.53 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 542.66m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 543.56m | 41.00 | -- | 2.41 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 561.70m | 166.00 | -- | 14.94 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 571.85m | 138.00 | -- | 1.54 | -- | 531.95 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 70.86m | -68.58m | 571.98m | 103.00 | -- | 3.96 | -- | 8.07 | -0.1894 | -0.1894 | 0.1954 | 0.3307 | 0.2689 | 1.06 | 27.10 | 688,000.00 | -26.02 | -55.75 | -29.23 | -66.32 | 99.41 | 95.36 | -96.77 | -1,103.37 | 5.63 | -6.58 | 0.3199 | -- | 2,481.48 | -37.35 | -13.15 | -- | 71.25 | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 572.49m | 55.00 | -- | 2.87 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 592.41m | 409.00 | -- | -- | -- | 21.61 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| ProKidney Corp | 744.00k | -71.03m | 595.65m | 204.00 | -- | -- | -- | 800.61 | -0.5443 | -0.5443 | 0.0057 | -3.41 | 0.0018 | -- | 0.2347 | 3,647.06 | -38.54 | -- | -- | -- | -- | -- | -21,403.63 | -- | -- | -- | 0.0003 | -- | -- | -- | -72.51 | -- | -- | -- |
| Prime Medicine Inc | 5.98m | -197.34m | 599.30m | 214.00 | -- | 3.70 | -- | 100.27 | -1.44 | -1.44 | 0.0434 | 0.8975 | 0.0167 | -- | -- | 27,929.91 | -54.98 | -64.35 | -61.20 | -77.73 | -- | -- | -3,301.64 | -8,356.07 | -- | -- | 0.00 | -- | -- | -- | 1.14 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 604.50m | 15.00 | -- | 9.73 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Design Therapeutics Inc's reporting currency: US Dollar USD
29.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Point72 Asset Management LPas of 30 Sep 2025 | 3.35m | 5.87% |
| Logos Global Management LPas of 18 Nov 2025 | 2.50m | 4.39% |
| Tang Capital Management LLCas of 30 Sep 2025 | 1.78m | 3.13% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.78m | 3.12% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 1.71m | 3.01% |
| Almitas Capital LLCas of 30 Sep 2025 | 1.53m | 2.69% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.44m | 2.52% |
| Driehaus Capital Management LLCas of 30 Sep 2025 | 1.08m | 1.89% |
| Kynam Capital Management LPas of 30 Sep 2025 | 1.03m | 1.81% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 740.85k | 1.30% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
